title: Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
abstract: Acute myeloid leukemia (AML) has posed significant therapeutic challenges to pediatric oncologists. Despite intensive therapy, half of the children with AML relapse and die from their disease. Efforts to identify risk factors in AML are directed toward defining populations who may benefit from alternative therapies. Patients at lower risk for relapse may benefit from treatment de-escalation, sparing them adverse side effects. Management of high-risk patients may prove more difficult, as the nearly myeloablative nature of AML therapy leaves little room for therapy escalation short of stem cell transplantation. This review evaluates prognostic factors in pediatric AML and discusses the feasibility of using these factors in risk-adapted therapy regimens.
authors.affiliation: Fred Hutchinson Cancer Research Center, University of Washington, Department of Pediatrics, Division of Clinical Research, Seattle, Washington, USA.
authors.forename: Soheil
authors.initials: S
authors.lastname: Meshinchi
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Arceci
mesh_terms: D000208:Acute Disease; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D033581:Stem Cell Transplantation
chemical_list: D000970:Antineoplastic Agents